Sarepta Therapeutics, Inc. (SRPT)
$
20.34
-0.90 (-4.42%)
Key metrics
Financial statements
Free cash flow per share
-3.8792
Market cap
2.3 Billion
Price to sales ratio
0.9625
Debt to equity
0.9470
Current ratio
2.9545
Income quality
0.9010
Average inventory
1 Billion
ROE
-0.2031
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for rare diseases. The diluted EPS is $2.34 accounting for potential share dilution. The financial data pertains to the fiscal year 2024 reflecting the overall performance of the company. The income before tax ratio is 0.14 which showcases the pre-tax margin and operational efficiency of Sarepta. Furthermore, the cost of revenue for the company is $319,099,000.00 highlighting its production and operational expenses. Despite these costs, the company earned an interest income of $71,767,000.00 showcasing its financial investments and ability to generate additional revenue streams. Sarepta offers the EXONDYS 51 injection and VYONDYS 53 for the treatment of Duchenne muscular dystrophy in patients with specific confirmed mutations in the dystrophin gene. The company is also progressing in developing AMONDYS 45, SRP-5051, SRP-9001, and SRP-9003, thereby solidifying its commitment to addressing rare genetic diseases through innovative therapies. Currently, the stock is reasonably priced at $17.43 appealing to a broad range of investors. This attractiveness is further supported by an average trading volume of 4,045,450.00 indicating moderate liquidity for potential and existing shareholders. With a mid-range market capitalization of $2,131,367,580.00 the company is a steady performer in its sector. It is a key player in the biotechnology industry, contributing significantly to the overall market landscape, while also driving innovation and growth in the healthcare sector. Through its collaborations with multiple organizations, Sarepta continues to enhance its research and development capabilities, positioning itself as a leader in genetic therapies and a vital contributor to advancements aimed at treating rare diseases.
Is Sarepta Therapeutics, Inc. (SRPT) a good investment?
Investing in Sarepta Therapeutics, Inc. (SRPT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Sarepta Therapeutics, Inc. (SRPT)'s stock forecast?
Analysts predict Sarepta Therapeutics, Inc. stock to fluctuate between $10.42 (low) and $120.05 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Sarepta Therapeutics, Inc.'s market capitalization?
As of 2026-02-02, Sarepta Therapeutics, Inc.'s market cap is $2,131,367,580, based on 104,787,000 outstanding shares.
How does Sarepta Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Sarepta Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Sarepta Therapeutics, Inc. (SRPT) stock?
To buy Sarepta Therapeutics, Inc. (SRPT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SRPT. Place an order (Market, Limit, etc.).
What is the best time to invest in Sarepta Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Sarepta Therapeutics, Inc. stock ever split?
Sarepta Therapeutics, Inc.'s last stock split was 1:6 on 2012-07-12.
How did Sarepta Therapeutics, Inc. perform in the last earnings report?
Revenue: $1,901,979,000 | EPS: $2.47 | Growth: -142.59%.
Where can I find Sarepta Therapeutics, Inc.'s investor relations reports?
Visit https://www.sarepta.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Sarepta Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Sarepta Therapeutics, Inc. stock?
All-time high: $173.25 (2024-06-21) | All-time low: $10.42 (2025-07-24).
What are the key trends affecting Sarepta Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.
seekingalpha.com
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
zacks.com
Sarepta Therapeutics (SRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
proactiveinvestors.com
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares moved higher in early trade on Monday as it reported positive topline three-year results from its Phase 3 EMBARK study evaluating its gene therapy ELEVIDYS in ambulatory patients with Duchenne muscular dystrophy. Sarepta said patients treated with ELEVIDYS demonstrated statistically significant and clinically meaningful slowing of disease progression across key functional measures compared with an untreated external control group.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 3-year topline functional results from patients treated in Part 1 of EMBARK (Study 9001-301), the global, randomized placebo-controlled Phase 3 study evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory individ.
fool.com
Sarepta Therapeutics' drug safety issues are overshadowing its innovative platform. Teladoc Health's financial results continue to worsen, and the stock looks unlikely to recover.
seekingalpha.com
Sarepta Therapeutics remains highly volatile as ELEVIDYS sales drive sentiment, with Q4 revenue missing expectations and safety concerns lingering. Despite fading ELEVIDYS sales, SRPT management reiterates a $500M annual revenue floor and expects normalization in ambulatory demand to support growth. SRPT fundamentals are robust, with nearly $1B in cash, no near-term debt, and a stable PMO franchise generating almost $1B in 2025 revenue.
seekingalpha.com
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
newsfilecorp.com
San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) concerning whether certain officers and directors breached their fiduciary duties to the Company and its shareholders. The investigation follows the filing of a securities class action involving purchases of Sarepta securities between June 22, 2023 and June 24, 2025 (the "Class Period").
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial application (CTA) for Study SRP-1005-101, also known as INSIGHTT, to Medsafe, the New Zealand Medicines and Medical Devices Safety Authority. Pending approval, Sarepta expects to initiate this first-in-human clinical trial of SRP-1005 (formerly ARO-HTT) in the second quarter of 2026. SRP-1005 is an investiga.
See all news
